HRP20180685T1 - Antitijelo protiv humanog dlk-1 koje posjeduje protutumorsko djelovanje in vivo - Google Patents
Antitijelo protiv humanog dlk-1 koje posjeduje protutumorsko djelovanje in vivoInfo
- Publication number
- HRP20180685T1 HRP20180685T1 HRP20180685TT HRP20180685T HRP20180685T1 HR P20180685 T1 HRP20180685 T1 HR P20180685T1 HR P20180685T T HRP20180685T T HR P20180685TT HR P20180685 T HRP20180685 T HR P20180685T HR P20180685 T1 HRP20180685 T1 HR P20180685T1
- Authority
- HR
- Croatia
- Prior art keywords
- vivo
- antibody
- tumor activity
- human dlk
- dlk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261709282P | 2012-10-03 | 2012-10-03 | |
| EP13843070.7A EP2905335B1 (en) | 2012-10-03 | 2013-10-03 | Anti-human dlk-1 antibody having anti-tumor activity in vivo |
| PCT/JP2013/077540 WO2014054820A1 (ja) | 2012-10-03 | 2013-10-03 | in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180685T1 true HRP20180685T1 (hr) | 2018-06-01 |
Family
ID=50435137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180685TT HRP20180685T1 (hr) | 2012-10-03 | 2018-04-30 | Antitijelo protiv humanog dlk-1 koje posjeduje protutumorsko djelovanje in vivo |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9303086B2 (hr) |
| EP (1) | EP2905335B1 (hr) |
| JP (1) | JP6280040B2 (hr) |
| KR (1) | KR102149565B1 (hr) |
| CN (1) | CN104704119B (hr) |
| AU (1) | AU2013325443B2 (hr) |
| CA (1) | CA2886772C (hr) |
| CY (1) | CY1120063T1 (hr) |
| DK (1) | DK2905335T3 (hr) |
| ES (1) | ES2665341T3 (hr) |
| HR (1) | HRP20180685T1 (hr) |
| HU (1) | HUE037274T2 (hr) |
| LT (1) | LT2905335T (hr) |
| NO (1) | NO2972360T3 (hr) |
| PL (1) | PL2905335T3 (hr) |
| PT (1) | PT2905335T (hr) |
| RS (1) | RS57120B1 (hr) |
| SI (1) | SI2905335T1 (hr) |
| WO (1) | WO2014054820A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101619862B1 (ko) * | 2014-09-30 | 2016-05-12 | 주식회사 녹십자 | 간접효소면역측정법을 이용하는 인간 Fc 포함 단백질의 역가 측정키트 및 이를 이용한 Fc 포함 단백질의 역가 측정방법 |
| PT3579883T (pt) | 2017-02-08 | 2021-09-28 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
| EP3683236A4 (en) * | 2017-09-08 | 2021-10-13 | Y-Biologics Inc. | ANTIBODIES TO HUMANES DLK1 AND ITS USES |
| AU2020255907A1 (en) | 2019-04-01 | 2021-10-28 | Chiome Bioscience Inc. | Medicament for treating cancer |
| KR20230083296A (ko) | 2020-10-05 | 2023-06-09 | 치오메 바이오사이언스 가부시키가이샤 | 암 치료용 의약 |
| AU2022271741A1 (en) | 2021-05-10 | 2023-11-23 | Chiome Bioscience Inc. | Purification method of antibody composition |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| AU665025B2 (en) * | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| EP1013762A3 (en) | 1992-12-11 | 2000-10-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Delta-like gene expressed in neuroendocrine tumors |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| JP2001269174A (ja) | 2000-03-24 | 2001-10-02 | Kirin Brewery Co Ltd | 骨髄異形成症候群（ｍｄｓ）の検出方法及びｍｄｓの治療剤 |
| US20030185815A1 (en) | 2001-04-03 | 2003-10-02 | Muralidhara Padigaru | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| US20040241170A1 (en) | 2001-08-24 | 2004-12-02 | Jensen Charlotte Harken | Isolation of cells from neural cell populations using antibodies to fa1/dlk1 |
| EP2287198A3 (en) * | 2002-03-13 | 2011-05-25 | Biogen Idec MA Inc. | Anti-alpha V beta 6 antibodies |
| AU2003215525A1 (en) | 2002-03-21 | 2003-10-08 | Nsgene A/S | Detection and isolation of cell populations from muscle using antibodies to fa1/dlk1 |
| JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
| AU2003295328A1 (en) | 2002-10-02 | 2004-04-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| JP4695982B2 (ja) | 2003-11-28 | 2011-06-08 | 財団法人神奈川科学技術アカデミー | 肝癌の検出方法及び肝癌診断薬並びに癌治療薬 |
| CN101631802B (zh) * | 2006-11-10 | 2014-03-05 | 株式会社立富泰克 | 在体内具有抗肿瘤活性的抗人Dlk-1抗体 |
| ES2527521T3 (es) | 2008-03-17 | 2015-01-26 | Livtech Inc. | Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral |
| WO2011104604A2 (en) * | 2010-02-23 | 2011-09-01 | Glenmark Pharmaceuticals S.A. | Anti-alpha2 integrin antibodies and their uses |
| TWI651331B (zh) * | 2010-05-04 | 2019-02-21 | 戊瑞治療有限公司 | 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類 |
-
2013
- 2013-10-03 JP JP2014539861A patent/JP6280040B2/ja active Active
- 2013-10-03 WO PCT/JP2013/077540 patent/WO2014054820A1/ja active Application Filing
- 2013-10-03 AU AU2013325443A patent/AU2013325443B2/en active Active
- 2013-10-03 CN CN201380051895.5A patent/CN104704119B/zh active Active
- 2013-10-03 KR KR1020157009420A patent/KR102149565B1/ko active IP Right Grant
- 2013-10-03 HU HUE13843070A patent/HUE037274T2/hu unknown
- 2013-10-03 RS RS20180437A patent/RS57120B1/sr unknown
- 2013-10-03 DK DK13843070.7T patent/DK2905335T3/en active
- 2013-10-03 PT PT138430707T patent/PT2905335T/pt unknown
- 2013-10-03 CA CA2886772A patent/CA2886772C/en active Active
- 2013-10-03 PL PL13843070T patent/PL2905335T3/pl unknown
- 2013-10-03 US US14/045,326 patent/US9303086B2/en active Active
- 2013-10-03 SI SI201330954T patent/SI2905335T1/en unknown
- 2013-10-03 ES ES13843070.7T patent/ES2665341T3/es active Active
- 2013-10-03 EP EP13843070.7A patent/EP2905335B1/en active Active
- 2013-10-03 LT LTEP13843070.7T patent/LT2905335T/lt unknown
-
2014
- 2014-03-14 NO NO14721647A patent/NO2972360T3/no unknown
-
2018
- 2018-03-23 CY CY20181100334T patent/CY1120063T1/el unknown
- 2018-04-30 HR HRP20180685TT patent/HRP20180685T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2905335T1 (en) | 2018-04-30 |
| KR102149565B1 (ko) | 2020-08-28 |
| PT2905335T (pt) | 2018-03-12 |
| EP2905335B1 (en) | 2018-01-31 |
| CA2886772A1 (en) | 2014-04-10 |
| PL2905335T3 (pl) | 2018-06-29 |
| CN104704119B (zh) | 2017-09-05 |
| EP2905335A1 (en) | 2015-08-12 |
| JPWO2014054820A1 (ja) | 2016-08-25 |
| CN104704119A (zh) | 2015-06-10 |
| RS57120B1 (sr) | 2018-06-29 |
| DK2905335T3 (en) | 2018-03-12 |
| CA2886772C (en) | 2021-01-12 |
| LT2905335T (lt) | 2018-04-10 |
| ES2665341T3 (es) | 2018-04-25 |
| NO2972360T3 (hr) | 2018-08-04 |
| US20140193432A1 (en) | 2014-07-10 |
| AU2013325443B2 (en) | 2019-01-31 |
| HUE037274T2 (hu) | 2018-08-28 |
| KR20150060761A (ko) | 2015-06-03 |
| US9303086B2 (en) | 2016-04-05 |
| EP2905335A4 (en) | 2016-05-18 |
| CY1120063T1 (el) | 2018-12-12 |
| JP6280040B2 (ja) | 2018-02-14 |
| AU2013325443A1 (en) | 2015-04-09 |
| WO2014054820A1 (ja) | 2014-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281250A (en) | Anti-PHF-tau antibodies and uses thereof | |
| HRP20180640T1 (hr) | Anti-b7-h3 antitijelo | |
| EP2799452A4 (en) | ANTIBODY AGAINST HUMAN TROP-2 WITH ANTITUMOUS EFFECT IN VIVO | |
| IL259826A (en) | Anti-alphabetatisiar antibody | |
| EP2749572A4 (en) | NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY | |
| EP2573120A4 (en) | ANTIBODY AGAINST HUMAN TROP-2 WITH IN VIVO ANTITUMOR EFFECT | |
| EP2756094A4 (en) | ANTI-B7-H4 ANTIBODIES AND USES THEREOF | |
| AP2014008102A0 (en) | Anti-FcRn antibodies | |
| HRP20180685T1 (hr) | Antitijelo protiv humanog dlk-1 koje posjeduje protutumorsko djelovanje in vivo | |
| TWI563004B (en) | Anti-hxcr1 antibody | |
| EP2720718A4 (en) | ANTI-CD3 THERAPIES | |
| EP2769988A4 (en) | ANTI-GAP43 ANTIBODY | |
| GB201107656D0 (en) | Short back and sides | |
| HUP1100282A2 (en) | Protein factor | |
| GB201107773D0 (en) | Travel playpen |